Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Whelan

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
European Urology|August 13, 2013
Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-upUrs E Studer, Peter Whelan, Florian Wimpissinger, et al.
Plos Neglected Tropical Diseases|February 14, 2017
Holding back the tiger: Successful control program protects Australia from Aedes albopictus expansionMutizwa Odwell Muzari, Gregor Devine, Joseph Davis, et al.
European Urology|January 15, 2008
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)Urs E Studer, Laurence Collette, Peter Whelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891Urs E Studer, Peter Whelan, Walter Albrecht, et al.
European Urology|March 26, 2004
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892Fritz H Schröder, Peter Whelan, Theo M de Reijke, et al.
Plos One|March 28, 2014
A new species of mesonivirus from the Northern Territory, AustraliaDavid Warrilow, Daniel Watterson, Roy A Hall, et al.
European Urology|April 16, 2013
Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological GroupFernando Calais da Silva, Fernando Manuel Calais da Silva, Frederico Gonçalves, et al.
European Urology|March 3, 2009
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological GroupFernando E C Calais da Silva, Aldo V Bono, Peter Whelan, et al.
BJU International|November 15, 2008
The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinomaRobin J Prestwich, Karen J Scott, Joanne Brown, et al.
Evolutionary Bioinformatics Online|October 13, 2010
Molecular phylogeny of edge hill virus supports its position in the yellow Fever virus group and identifies a new genetic variantJoanne Macdonald, Michael Poidinger, John S Mackenzie, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
European Urology|August 13, 2013
Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-upUrs E Studer, Peter Whelan, Florian Wimpissinger, et al.
Plos Neglected Tropical Diseases|February 14, 2017
Holding back the tiger: Successful control program protects Australia from Aedes albopictus expansionMutizwa Odwell Muzari, Gregor Devine, Joseph Davis, et al.
European Urology|January 15, 2008
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)Urs E Studer, Laurence Collette, Peter Whelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891Urs E Studer, Peter Whelan, Walter Albrecht, et al.
European Urology|March 26, 2004
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892Fritz H Schröder, Peter Whelan, Theo M de Reijke, et al.
Plos One|March 28, 2014
A new species of mesonivirus from the Northern Territory, AustraliaDavid Warrilow, Daniel Watterson, Roy A Hall, et al.
European Urology|April 16, 2013
Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological GroupFernando Calais da Silva, Fernando Manuel Calais da Silva, Frederico Gonçalves, et al.
European Urology|March 3, 2009
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological GroupFernando E C Calais da Silva, Aldo V Bono, Peter Whelan, et al.
BJU International|November 15, 2008
The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinomaRobin J Prestwich, Karen J Scott, Joanne Brown, et al.
Evolutionary Bioinformatics Online|October 13, 2010
Molecular phylogeny of edge hill virus supports its position in the yellow Fever virus group and identifies a new genetic variantJoanne Macdonald, Michael Poidinger, John S Mackenzie, et al.
Pageof 5